Opposite effect of stable transfection of bioactive transforming growth factor-β1 (TGFβ1) versus exogenous TGFβ1 treatment on expression of 92-kDa type IV collagenase in mouse skin squamous cell carcinoma CH72 cells

Molecular Carcinogenesis

Volumn 19, Issue 2, 1997, Pages 122-136

  Rundhaug, Joyce E ^a   Park, Jeanie ^a   Pavone, Amy ^a   Opdenakker, Ghislain ^b   Fischer, Susan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Gelatinase B; Matrix metalloproteinase 9; Mouse skin carcinogenesis model; Transforming growth factor 1; Type IV collagenase

Indexed keywords

GELATINASE A; GELATINASE B; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BLOCKING; BLOTTING, NORTHERN; CARCINOMA, SQUAMOUS CELL; COLLAGENASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MUTATION; PAPILLOMA; RNA, MESSENGER; SKIN NEOPLASMS; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

ANIMALIA; TRIXIS;

EID: 0030751184     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199707)19:2<122::AID-MC7>3.0.CO;2-H     Document Type: Article

References (72)

1. Farber E. Cellular biochemistry of the stepwise development of cancer with chemicals: G.H.A. Clowes Memorial Lecture. Cancer Res 44:5463-5474, 1984.
2. Fischer SM, Reiners JJ Jr, Pence BC, et al. Mechanisms of carcinogenesis using mouse skin: The multistage assay revisited. In: Langenbach R, Elmore E, Barrett JC (eds), Tumor Promoters: Biological Approaches for Mechanistic Studies and Assay Systems. Raven Press, New York, 1988, pp. 11-30.
3. Sugimura T. Multistep carcinogenesis: A 1992 perspective. Science 258:603-607, 1992.
4. Yuspa SH. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis - Thirty-third G.H.A. Clowes Memorial Award Lecture. Cancer Res 54:1178-1189, 1994.
5. Kohn EC, Liotta LA. Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 55:1856-1862, 1995.
6. Massagué J. The transforming growth factor-β family. Annu Rev Cell Biol 6:597-641, 1990.
7. Roberts AB, Sporn MB. The transforming growth factor-betas. In: Sporn MB, Roberts AB (eds), Peptide Growth Factors and Their Receptors. Springer-Verlag, Heidelberg, 1990, pp. 419-472.
8. Coffey RJ Jr, Sipes NJ, Bascom CC, et al. Growth modulation of mouse keratinocytes by transforming growth factors. Cancer Res 48:1596-1602, 1988.
9. Kane CJM, Knapp AM, Mansbridge JN, Hanawalt PC. Transforming growth factor-β1 localization in normal and psoriatic epidermal keratinocytes in situ. J Cell Physiol 144:144-150, 1990.
10. Kane CJM, Hebda PA, Mansbridge JN, Hanawalt PC. Direct evidence for spatial and temporal regulation of transforming growth factor β1 expression during cutaneous wound healing. J Cell Physiol 148:157-173, 1991.
11. Patamalai B, Burow DL, Gimenez-Conti I, et al. Altered expression of transforming growth factor-β1 mRNA and protein in mouse skin carcinogenesis. Mol Carcinog 9:220-229, 1994.
12. Haddow S, Fowlis DJ, Parkinson K, Akhurst RJ, Balmain A. Loss of growth control by TGF-β occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene activation. Oncogene 6:1465-1470, 1991.
13. Krieg P, Schnapke R, Fürstenberger G, Vogt l, Marks F. TGF-β1 and skin carcinogenesis: Antiproliferative effect in vitro and TGF-β1 mRNA expression during epidermal hyperproliferation and multistage tumorigenesis. Mol Carcinog 4:129-137, 1991.
14. Hubbs AF, Hahn FF, Thomassen DG. Increased resistance to transforming growth factor beta accompanies neoplastic progression of rat tracheal epithelial cells. Carcinogenesis 10:1599-1605, 1989.
15. Game SM, Stone A, Scully C, Prime SS. Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF-β receptor expression and altered responses to these growth factors. Carcinogenesis 11:965-973, 1990.
16. Wyllie FS, Dawson T, Bond JA, et al. Correlated abnormalities of transforming growth factor-β1 response and p53 expression in thyroid epithelial cell transformation. Mol Cell Endocrinol 76:13-21, 1991.
17. Huggett AC, Ellis PA, Ford CP, Hampton LL, Rimoldi D, Thorgeirsson SS. Development of resistance to the growth inhibitory effects of transforming growth factor β1 during the spontaneous transformation of rat liver epithelial cells. Cancer Res 51:5929-5936, 1991.
18. Schwarz LC, Gingras M-C, Goldberg G, Greenberg AH, Wright JA. Loss of growth factor dependence and conversion of transforming growth factor-β1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res 48:6999-7003, 1988.
19. Hsu S, Huang F, Hafez M, Winawer S, Friedman E. Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression. Cell Growth Differ 5:267-275, 1994.
20. Fowlis DJ, Flanders KC, Duffie E, Balmain A, Akhurst RJ. Discordant transforming growth factor β1 RNA and protein localization during chemical carcinogenesis of the skin. Cell Growth Differ 3:81-91, 1992.
21. Fürstenberger G, Rogers M, Schnapke R, Bauer G, Höfler P, Marks F. Stimulatory role of transforming growth factors in multistage skin carcinogenesis: Possible explanation for the tumor-inducing effect of wounding in initiated NMRI mouse skin. Int J Cancer 43:915-921, 1989.
22. Cui W, Fowlis DJ, Bryson S, et al.TGFβl inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531-542, 1996.
23. Glick AB, Kulkarni AB, Tennenbaum T, et al. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 90:6076-6080, 1993.
24. null mice is prognostic for a high risk of malignant conversion. Cancer Res 54:5831-5836, 1994.
25. Glick AB, Lee MM, Darwiche N, Kulkarni AB, Karlsson S, Yuspa SH. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 8:2429-2440, 1994.
26. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immuno-histochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 52:6949-6952, 1992.
27. Dalai Bl, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-βl to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143:381-389, 1993.
28. Schwarz LC, Wright JA, Gingras M-C, et al. Aberrant TGF-β production and regulation in metastatic malignancy. Growth Factors 3:115-127, 1990.
29. Roberts AB, Sporn MB. Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-β. Am Rev Respiratory Dis 140:1126-1128, 1989.
30. Ueki N, Nakazato M, Ohkawa T, et al. Excessive production of transforming growth factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1137:189-196, 1992.
31. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114:521-532, 1992.
32. Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes: Implications for normal and impaired wound healing. J Biol Chem 270:12607-12613, 1995.
33. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 269:6271-6274, 1994.
34. Akedo H, Shinkai K, Mukai M, Komatsu K. Potentiation and inhibition of tumor cell invasion by host cells and mediators. Invasion Metastasis 9:134-148, 1989.
35. Welch DR, Fabra A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87:7678-7682, 1990.
36. Agarwal C, Hembree JR, Rorke EA, Eckert RL. Transforming growth factor β1 regulation of metalloproteinase production in cultured human cervical epithelial cells. Cancer Res 54:943-949, 1994.
37. r 72,000 type IV collagenase and interstitial collagenase in human tumorigeniccell lines. Cancer Res 50:6184-6191, 1990.
38. Salo T, Lyons JG, Rahemtulla F, Birkedal-Hansen H, Larjava H. Transforming growth factor-β1 up-regulates type IV collagenase expression in cultured human keratinocytes. J Biol Chem 266:11436-11441, 1991.
39. Samuel SK, Hurta RAR, Kondaiah P, et al. Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF-β1 (Ser223,225). EMBO J 11:1599-1605, 1992.
40. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-68, 1980.
41. Yamagata S, Tanaka R, Ito Y, Shimizu S. Gelatinases of murine metastatic tumor cells. Biochem Biophys Res Commun 158:228-234, 1989.
42. r 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 50:3872-3877, 1990.
43. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 71:1368-1383, 1993.
44. Brunner AM, Marquardt H, Malacko AR, Lioubin MN, Purchio AF. Site-directed mutagenesis of cysteme residues in the pro region of the transforming growth factor β1 precursor: Expression and characterization of mutant proteins. J Biol Chem 264:13660-13664, 1989.
45. Conti CJ, Fries JW, Viaje A, Miller DR, Morris R, Slaga TJ. In vivo behavior of murine epidermal cell lines derived from initiated and noninitiated skin. Cancer Res 48:435-439, 1988.
46. Lopez AR, Cook J, Deininger PL, Derynck R. Dominant negative mutants of transforming growth factor-β1 inhibit the secretion of different transforming growth factor-β isoforms. Mol Cell Biol 12:1674-1679, 1992.
47. Sambrook J, Fritsch EF, Maniatis T. In: Molecular Cloning: A Laboratory Manual, Vol. 3. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, pp. 16.32-16.36.
48. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987.
49. Masure S, Nys G, Fiten P, Van Damme J, Opdenakker G. Mouse gelatinase B: cDNA cloning, regulation of expression and glycosylation in WEHI-3 macrophages and gene organisation. Eur J Biochem 218:129-141, 1993.
50. Balmain A, Krumlauf R, Vass JK, Birnie GD. Cloning and characterisation of the abundant cytoplasmic 7S RNA from mouse cells. Nucleic Acids Res 10:4259-4277, 1982.
51. Reisenbichler H, Jirtle RL. BSA treatment of plasticware reduces TGFβ binding. Biotechniques 17:675-676, 1994.
52. Tanaka H, Hojo K, Yoshida H, Yoshioka T, Sugita K. Molecular cloning and expression of the mouse 105-kDa gelatinase cDNA. Biochem Biophys Res Commun 190:732-740, 1993.
53. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154, 1991.
54. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63:51 5-524, 1990.
55. Rundhaug JE, Park J, Fischer SM. Uncoordinated regulation of the mRNA expression of the three isoforms of transforming growth factor-β in the mouse skin carcinogenesis model. Mol Carcinog, 18:115-126, 1997.
56. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE. Transforming growth factor β enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA 90:4577-4581, 1993.
57. MacDougall JR, Bani MR, Lin Y, Rak J, Kerbel RS. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 55:4174-4181, 1995.
58. Pyke C, Ralfkiær E, Huhtala P, Hurskainen T, Danø K, Tryggvason K. Localization of messenger RNA for H 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 52:1336-1341, 1992.
59. Okada A, Santavicca M, Basset P. The cDNA cloning and expression of the gene encoding rat gelatinase B. Gene 164:317-321, 1995.
60. Sharpies K, Plowman GD, Rose TM, Twardzik DR, Purchio AF. Cloning and sequence analysis of simian transforming growth factor-β cDNA. DNA 6:239-244, 1987.
61. Derynck R, Jarrett JA, Chen EY, Goeddel DV. The murine transforming growth factor-β precursor. J Biol Chem 261:4377-4379, 1986.
62. Cui W, Fowlis DJ, Cousins FM, et al. Concerted action of TGF-β1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Dev 9:945-955, 1995.
63. Fowlis DJ, Cui W, Johnson SA, Baimain A, Akhurst RJ. Altered epidermal cell growth control in vivo by inducible expression of transforming growth factor β1 in the skin of transgenic mice. Cell Growth Differ 7:679-687, 1996.
64. Bassing CH, Yingling JM, Howe DJ, et al. A transforming growth factor β type I receptor that signals to activate gene expression. Science 263:87-89, 1994.
65. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-β receptor. Nature 370:341-347, 1994.
66. Brand T, Schneider MD. Inactive type II and type I receptors for TGFβ are dominant inhibitors of TGFβ-dependent transcription. J Biol Chem 270:8274-8284, 1995.
67. Koli K, Arteaga CL. Predominant cytosolic localization of TGFβ-type II receptors (IIR) in human breast carcinoma cells. Proc Am Assoc Cancer Res 37:37, 1996.
68. Caulin C, Scholl FG, Frontelo P, Gamallo C, Quintanilla M. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-β1 induces an epithehal-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ 6:1027-1035, 1995.
69. Wu S, Theodorescu D, Kerbel RS, et al. TGF-β1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 116:187-196, 1992.
70. Wu SP, Sun L-Z, Willson JKV, Humphrey L, Kerbel R, Brattain MG. Repression of autocrine transforming growth factor β1 and β2 in qutescenT~CBS colon carcinoma cells leads to pro- gression of tumongenic properties. Cell Growth Differ 4:115-123, 1993.
71. Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1.J Cell Biol 118:715-726, 1992.
72. Chang H-L, Gillett N, Figari l, Lopez AR, Palladino MA, Derynck R. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 53:4391-4398, 1993.